FDA Says Studies By Panexcell And Synchron “Unacceptable”
US Agency Warns Pharmaceutical Companies Against Using Firms’ Data
The US FDA has objected to studies conducted by India-based contract research organizations Panexcell Clinical Lab and Synchron Research Services, because of data integrity concerns. The FDA has warned pharmaceutical companies sponsoring drug application approvals, that data generated by Panexcell and Synchron will be “unacceptable.”
